The present inventive concept provides non-toxic compositions including ethanol, a polymer, and a polar aprotic solvent and methods of using the same in the field of preservation of plant, human and non-human animal tissue and anatomic pathology disciplines (e.g., surgical pathology, histopathology, cytopathology, forensic pathology). In particular, the compositions provide a safer alternative to aldehyde-based compositions.

A method for cryopreserving cells, a cell cryopreservation solution and a composition are provided. The method includes: providing a suspension for the cells to be cryopreserved in a cell cryopreservation solution; and cryopreserving the suspension. The cell cryopreservation solution includes dimethyl sulfoxide, plasma, citric acid, sodium citrate, potassium dihydrogen phosphate or sodium dihydrogen phosphate, glucose and adenine.

One aspect of the invention provides a method for harvesting adult cells from an organ. The method includes perfusing the organ with a perfusate and isolating adult cells from the organ, thereby harvesting the adult cells from the organ. Another aspect of the invention provides a method for rehabilitating an organ. The method includes: dividing the organ into a first portion and a second portion, perfusing the first portion with a decellularization medium, isolating adult cells from the second portion, and recellularizing the first portion with a suspension of the adult cells, thereby rehabilitating the organ.

Organ and tissue preservation solutions having improved stability are disclosed. The solutions are comprised of two separate solutions. The first solution, Solution A, is comprised of a balanced salt solution that is stable in solution at a pH of 7.0 or above. A second solution, Solution B, is comprised of an aqueous solution containing L-glutathione and/or cysteinylglycine, a sugar such as D-glucose, L-Arginine, a reducing agent such as ascorbic acid and water at a pH of below 7.0, preferably from about 3.0 to 5.0. The two Solutions are then mixed together at the point of use and the pH adjusted to about 7.3 resulting in the organ and tissue preservation solution having improved stability. Preferably, solution A has a pH of about 7.6 and solution B has a pH of about 5.0. The present invention is also comprised of kits 20 that contain the two Solutions in two separate containers 22, 24. In an alternate embodiment, the sugar can be in Solution A.

Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries. A method of formulating human RPE cells for administration to a subject directly after thawing and of formulating RPE cell therapy compositions for cryopreservation and administration of the cryopreserved composition to a subject subsequent to thawing are also presented. In another aspect, the RTA composition may be formulated as a thaw and inject (TAI) composition, whereby the composition is administered by injection subsequent to thawing.

Provided is a distribution method with which particle components such as cells can be dispensed. In one aspect, provided is a method for distributing particles, the method including dispersing the particles in a plastic fluid, and dispensing the plastic fluid containing the particles. In another aspect, provided is a method for producing a product including a particle and a container for the particle, the method including dispensing a plastic fluid in which the particles are dispersed, from a storage part in which the plastic fluid is stored, to a plurality of the containers.

This disclosure relates to subnormothermic machine perfusion formulations for ex vivo preservation of allografts, and methods of use thereof.

A nucleic acid preservation solution, a preparation method and application for same is disclosed. The nucleic acid preservation solution of the invention includes, by weight percentage, citric acid 13%-35%, Tween 20 0.50%-2.50%, disodium ethylene diamine tetraacetic acid (EDTA) 13%-40%, sodium sulfate 35%-70%, polyethylene glycol octyl phenyl ether 0.50%-2.50%, and the balance being diethylpyrocarbonate (DEPC) water.

A culture module is contemplated that allows the perfusion and optionally mechanical actuation of one or more microfluidic devices, such as organ-on-a-chip microfluidic devices comprising cells that mimic at least one function of an organ in the body. A method for pressure control is contemplated to allow the control of flow rate (while perfusing cells) despite limitations of common pressure regulators. The method for pressure control allows for perfusion of a microfluidic device, such as an organ on a chip microfluidic device comprising cells that mimic cells in an organ in the body, that is detachably linked with said assembly, so that fluid enters ports of the microfluidic device from a fluid reservoir, optionally without tubing, at a controllable flow rate.

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.